PYC Therapeutics Lands FDA clearance for first human trials of RP11 treatment drug
- PYC Pharmaceuticals (PYC) lands approval from the US FDA to begin human trials of a new drug to treat the blinding eye disease Retinitis Pigmentosa (RP11)
- The genetic disease affects around one in every 100,000 people, and no other treatment options currently exist
- PYC will now seek human ethics approval for its VP-001 drug before it kicks off the first human clinical trials for an RP11 treatment
- Provided its ethics application goes smoothly, PYC expects to dose the first of 10-15 trial participants before the end of June
- PYC shares are up 2.33 per cent and trading at 8.8 cents at 12:48 pm AEDT
